February 2021,
Astrazeneca, The Carnot Calym Institute and Inserm Transfert for Inserm sign a framework agreement for research collaboration in lymphomas.
Within three months of the agreement, two projects have already been lauched : INOVO and INTREPIDS.
The INOVO project will use an original model of diffuse large B-cell lymphoma (DLBCL) PDX (xenotransplant derived from patient tumors) developed by OncoFactory to screen and characterize the response of a panel of experimental molecules at the molecular level. This unique model will allow the study of patients’ cells in a rapid and reproducible manner. To know more
